Risk of developing hematologic malignancy in patients with autoimmune and inflammatory skin diseases - 19/01/26
Doi : 10.1016/j.jaad.2025.09.075
Jagmeet S. Arora, BS a, Aditya Mahadevan, MD b, Janellen Smith, MD a, Michelle S. Min, MD, MSci a, ⁎ 
a Department of Dermatology, University of California Irvine, Irvine, California
b Department of Medicine, University of California San Francisco, San Francisco, California
∗ Correspondence to: Michelle Min, MD, MSci, Director of Rheumatologic Dermatology, Department of Dermatology, University of California Irvine School of Medicine, 118 Medical Surge I, Irvine, CA 92697 Department of Dermatology University of California Irvine School of Medicine 118 Medical Surge I Irvine CA 92697
Key words : autoimmune blistering disorders, blood dyscrasias, connective tissue diseases, hematologic malignancy, monoclonal gammopathy, neutrophilic dermatoses, risk assessment
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Not applicable. |
© 2025
The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 94 - N° 2
P. 588-592 - février 2026 Retour au numéro
Article précédent
- Autoantibody testing practices and clinical implications in morphea: A 5-year multicenter retrospective study
- Maria Vazquez-Machado, Nikki Zangenah, Lorena A. Acevedo-Fontanez, Ellen Anshelevich, Rachael Rowley, William Crisler, Avery H. LaChance
- Association of glucagon-like peptide-1 agonist use with atopic dermatitis in obese patients: A retrospective cohort study
- Samantha M. Burke, Mara Beveridge, Betul Hatipoglu, Jennifer Murphy, Bryan T. Carroll
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?